Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02321930 · ClinicalTrials.gov registry record · Phase 4
Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT02321930 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 37 participants.
The verdict
NCT02321930, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.
Interventions
- DRUG tofacitinib 5mg po bid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2017-09-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02321930
The ClinicalTrials.gov registry entry for NCT02321930 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tofacitinib 5mg po bid is the first listed.
NCT02321930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02321930 about?
NCT02321930 is a clinical study titled "Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients". This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.
What is the current status of trial NCT02321930?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2016-02-16. Estimated completion is 2017-09-29.
What interventions are being tested in trial NCT02321930?
The interventions under investigation include: tofacitinib 5mg po bid (DRUG).
Who is sponsoring clinical trial NCT02321930?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.